REGENXBIO (RGNX) Panoramica del titolo
REGENXBIO Inc. è una società di biotecnologie in fase clinica che fornisce terapie geniche che forniscono geni funzionali a cellule con difetti genetici negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 0/6 |
RGNX Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di REGENXBIO Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$5.65 |
| Massimo di 52 settimane | US$16.19 |
| Minimo di 52 settimane | US$5.46 |
| Beta | 1.12 |
| Variazione di 1 mese | -40.46% |
| Variazione a 3 mesi | -29.73% |
| Variazione di 1 anno | -42.29% |
| Variazione a 3 anni | -72.48% |
| Variazione a 5 anni | -83.54% |
| Variazione dall'IPO | -81.45% |
Notizie e aggiornamenti recenti
Seeking Alpha • May 16
Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results
Summary REGENXBIO is downgraded from "Buy" to "Hold" due to regulatory setbacks and uncertain approval pathways. The company received a Complete Response Letter for RGX-121 (MPS II), faces an uncertain appeals process, and regulatory demands for more rigorous data. Positive phase 3 data for RGX-202 for DMD patients showed strong biomarker and functional results, but FDA Accelerated Approval on Surrogate endpoint remains uncertain for now. Upcoming catalysts include pivotal wet-AMD trial data in Q4 2026, but the cash runway only extends into early 2027, raising financing concerns. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 26
RGNX: Future Gene Therapy Milestones Will Test Regulatory Risk And Support Bullish Reassessment
REGENXBIO's consensus analyst price target has been revised lower, with cuts ranging from about $1 to $12 as analysts factor in updated clinical timelines, recent FDA commentary around RGX-121 and the approach to rare disease, as well as upcoming pivotal readouts for key gene therapy programs. Analyst Commentary Recent research updates show that while several firms still carry positive ratings on REGENXBIO, they have been trimming price targets and highlighting a more cautious setup around regulatory risk, clinical execution, and timelines for key programs.Recent updates
Seeking Alpha • May 16
Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results
Summary REGENXBIO is downgraded from "Buy" to "Hold" due to regulatory setbacks and uncertain approval pathways. The company received a Complete Response Letter for RGX-121 (MPS II), faces an uncertain appeals process, and regulatory demands for more rigorous data. Positive phase 3 data for RGX-202 for DMD patients showed strong biomarker and functional results, but FDA Accelerated Approval on Surrogate endpoint remains uncertain for now. Upcoming catalysts include pivotal wet-AMD trial data in Q4 2026, but the cash runway only extends into early 2027, raising financing concerns. Read the full article on Seeking AlphaAggiornamento della narrazione • Apr 26
RGNX: Future Gene Therapy Milestones Will Test Regulatory Risk And Support Bullish Reassessment
REGENXBIO's consensus analyst price target has been revised lower, with cuts ranging from about $1 to $12 as analysts factor in updated clinical timelines, recent FDA commentary around RGX-121 and the approach to rare disease, as well as upcoming pivotal readouts for key gene therapy programs. Analyst Commentary Recent research updates show that while several firms still carry positive ratings on REGENXBIO, they have been trimming price targets and highlighting a more cautious setup around regulatory risk, clinical execution, and timelines for key programs.Aggiornamento della narrazione • Apr 11
RGNX: Future Pivotal Gene Therapy Readouts Will Drive Bullish Reassessment
Analysts have nudged their average price target for REGENXBIO slightly lower to reflect recent target cuts across firms, while still highlighting upcoming regulatory updates and pivotal readouts in Duchenne muscular dystrophy and wet age related macular degeneration as key drivers for their updated views. Analyst Commentary Recent research updates show that while upcoming data and regulatory milestones remain central to the REGENXBIO story, several price targets have been adjusted lower following the latest quarterly results and clinical updates.Aggiornamento della narrazione • Mar 28
RGNX: Future Gene Therapy Milestones Will Drive Reassessment Despite Regulatory Uncertainty
Analysts have nudged their blended price target for REGENXBIO modestly lower by a few dollars to reflect recent reductions in firm level targets, while still pointing to upcoming regulatory updates and pivotal readouts across programs like RGX-202 and ABBV-RGX-314 as key factors in their outlook. Analyst Commentary Street research around REGENXBIO has tilted more cautious in recent weeks, with several price targets adjusted lower following the latest quarterly update, recent regulatory news and evolving views on the company’s gene therapy portfolio.Aggiornamento della narrazione • Mar 12
RGNX: Future Gene Therapy Readouts Will Drive Reassessment Despite Regulatory Setbacks
Analysts have trimmed their average price targets on REGENXBIO, with cuts such as $32 to $30, $45 to $42 and $18 to $17. These changes reflect updated assumptions for slightly lower revenue growth and profit margins, partly offset by a modestly lower discount rate and a higher future P/E multiple.Aggiornamento della narrazione • Feb 26
RGNX: Regulatory Resolution And Gene Therapy Data Will Drive Reassessment
Analysts have trimmed their price targets on REGENXBIO by up to $12, reflecting updated views on RGX-121 related regulatory uncertainty and revised assumptions for the discount rate, revenue growth, profit margin and future P/E, while the central fair value estimate remains at $12.00. Analyst Commentary Recent research updates around REGENXBIO have centered on RGX-121 and the regulatory commentary that investors are trying to interpret.Aggiornamento della narrazione • Feb 11
RGNX: Clinical Hold Setbacks Will Refocus Attention On Upcoming Pivotal Data
Analysts have trimmed their fair value estimate for REGENXBIO to $12.00 from $14.00, citing a reset in price targets across the Street following clinical updates. The revised estimate still reflects higher modeled revenue growth and a lower future P/E multiple in their assumptions.Articolo di analisi • Feb 06
REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • Jan 29
Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Dec 23
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 27% gain in the last month alone. The...Articolo di analisi • Oct 09
REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29%
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 29% gain in the last month alone...Articolo di analisi • Oct 03
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Aug 12
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel
NasdaqGS:RGNX 1 Year Share Price vs Fair Value Explore REGENXBIO's Fair Values from the Community and select yours With...
Aggiornamento della narrazione • Aug 08
Gene Therapy Breakthroughs Will Unlock Expanding Future Markets
Analysts have revised REGENXBIO’s price target downward to $29.75, reflecting heightened sector scrutiny after competitor safety issues but maintaining confidence in RGX-202’s differentiated immune suppression strategy and clinical outlook. Analyst Commentary Safety issues with a competitor's product (Sarepta's Elevidys) have renewed focus on immune prophylaxis, highlighting Regenxbio's proactive approach to immune suppression with RGX-202.Articolo di analisi • May 15
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for REGENXBIO Inc. ( NASDAQ:RGNX ), which a week ago released some disappointing...Articolo di analisi • May 01
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • Apr 24
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Nuova narrazione • Mar 30
FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline
Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments.Seeking Alpha • Mar 26
5 Reasons To Buy Regenxbio Right Now
Summary Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis. Technically speaking, the stock is shifting from bearish to bullish, with significant upside potential and positive price target trends from multiple analysts. RGNX is a prime buyout candidate, with AbbVie as a likely bidder, supported by several other potential suitors in the biotech and pharma sectors that are active/interested in Gene Therapy. Read the full article on Seeking AlphaArticolo di analisi • Mar 04
The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%
To the annoyance of some shareholders, REGENXBIO Inc. ( NASDAQ:RGNX ) shares are down a considerable 27% in the last...Seeking Alpha • Jan 15
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Summary Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku. Despite historical underperformance, I remain hopeful, banking on the durability of their wet AMD treatment and will continue buying at dips, giving RGNX stock two more years. Read the full article on Seeking AlphaArticolo di analisi • Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive
Unfortunately for some shareholders, the REGENXBIO Inc. ( NASDAQ:RGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 31
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Summary Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030. RGX-202 for the treatment of patients with DMD and ABBV-RGX-314 for treatment of patients with diabetic retinopathy are other programs in pipeline; Late-stage studies starting Q4 of 2024 and 1st half 2025 respectively. Read the full article on Seeking AlphaArticolo di analisi • Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Aug 06
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Summary Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the treatment of patients with MPS II, expected in the 2nd half of 2024. Initiation of a pivotal study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q4 of 2024. Subretinal delivery of ABBV-RGX-314 for the treatment of patients with Wet-AMD is ongoing; Two studies being done are ATMOSPHERE and ASCENT and regulatory submissions U.S. And EU on track for 1st half of 2026. Read the full article on Seeking AlphaArticolo di analisi • Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that REGENXBIO Inc. ( NASDAQ:RGNX ) filed its quarterly result this time last week. The...Articolo di analisi • Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
REGENXBIO Inc.'s ( NASDAQ:RGNX ) price-to-sales (or "P/S") ratio of 8.2x might make it look like a buy right now...Seeking Alpha • Jun 11
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Summary REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, and Hunter syndrome. ABBV-RGX-314, RGX-202, and RGX-121 are key pipeline candidates targeting significant markets with promising clinical data. The collaboration with AbbVie for ABBV-RGX-314 includes potential milestone payments and significant market potential in wet AMD and DR. I deem RGNX a "strong buy" due to its innovative pipeline, strategic partnerships, robust financial health, and potential market impact. Read the full article on Seeking AlphaArticolo di analisi • May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
The analysts might have been a bit too bullish on REGENXBIO Inc. ( NASDAQ:RGNX ), given that the company fell short of...Articolo di analisi • Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
The REGENXBIO Inc. ( NASDAQ:RGNX ) share price has softened a substantial 26% over the previous 30 days, handing back...Rendimenti per gli azionisti
| RGNX | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -43.9% | -1.8% | -0.3% |
| 1Y | -42.3% | 32.7% | 24.1% |
Ritorno vs Industria: RGNX ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 32.7 % nell'ultimo anno.
Rendimento vs Mercato: RGNX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 24.1 % nell'ultimo anno.
Volatilità dei prezzi
| RGNX volatility | |
|---|---|
| RGNX Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di RGNX è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 15% ) di RGNX è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2008 | 371 | Curran Simpson | www.regenxbio.com |
REGENXBIO Inc. è una società di biotecnologie in fase clinica che fornisce terapie geniche che forniscono geni funzionali a cellule con difetti genetici negli Stati Uniti. I suoi prodotti candidati alla terapia genica si basano sulla NAV Technology Platform, una piattaforma proprietaria per il rilascio di geni da parte di virus adeno-associati. I prodotti dell'azienda in fase di sviluppo includono ABBV-RGX-314 per il trattamento della degenerazione maculare senile umida, della retinopatia diabetica e di altre malattie croniche della retina; RGX-202 per il trattamento della distrofia muscolare di Duchenne e RGX-121 per il trattamento della mucopolisaccaridosi di tipo II.
REGENXBIO Inc. Riepilogo dei fondamenti
| RGNX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$295.71m |
| Utili (TTM) | -US$290.01m |
| Ricavi(TTM) | US$87.82m |
3.3x
Rapporto P/S-1.0x
Rapporto P/ERGNX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| RGNX Conto economico (TTM) | |
|---|---|
| Ricavi | US$87.82m |
| Costo del fatturato | US$260.49m |
| Profitto lordo | -US$172.66m |
| Altre spese | US$117.35m |
| Utili | -US$290.01m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -5.61 |
| Margine lordo | -196.61% |
| Margine di profitto netto | -330.23% |
| Rapporto debito/patrimonio netto | 841.1% |
Come si è comportato RGNX nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/18 00:30 |
| Prezzo dell'azione a fine giornata | 2026/05/18 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
REGENXBIO Inc. è coperta da 24 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |